Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development In Brief: smokers and beta carotene; PUFA-enriched formula; antioxidants no boost for conception; vitamin D misses on blood pressure

This article was originally published in The Tan Sheet

Executive Summary

Smokers’ beta carotene-mortality connection explored; PUFA-enriched infant formula speeds processing; antioxidants do not boost conception chances; and vitamin D does not lower blood pressure.

You may also be interested in...



Antioxidants/Cancer Health Claim Contradicted By ATBC Study - FDA

Analyses from the 1994 Alpha-Tocopherol, Beta Carotene intervention trial raise "serious questions" about vitamin E's role in modifying cancer risk, FDA's Center for Food Safety & Applied Nutrition concludes May 4 in rejecting an antioxidant vitamins/cancer health claim.

CARET trial subgroup data suggest lung cancer link to alcohol use among smokers.

BETA CAROTENE LINK TO LUNG CANCER MAY BE INFLUENCED BY ALCOHOL CONSUMPTION among smokers, suggests a new analysis of the Beta Carotene and Retinol Efficacy Trial (CARET) published in the Nov. 6 issue of the Journal of the National Cancer Institute. CARET, a six-center chemoprevention trial, was halted 21 months early because of interim data showing evidence of no benefit and possible harm in participants taking beta carotene (30 mg) and vitamin A (25,000 IU) daily for an average of four years ("The Tan Sheet" Jan. 22, p. 4). The study found 28% more lung cancers and 17% more deaths in the supplement group compared to the placebo group.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel